Write a PREreview

Relevance of Seasonal Revaccination against Respiratory Syncytial Virus in Hematology Patients: First Insights in Stem Cell Transplant Recipients

by Rabah Redjoul, Laurent Softic, Ludovic Cabanne, Gaëlle Sandillon, Christine Robin, Mohamed Ader, Clément Ourghanlian, Karishma Soocheta, Alexandre Soulier, Slim Fourati, and Sébastien Maury

Posted: September 10, 2026
Server: medRxiv
DOI: 10.64898/2026.09.08.26362495

Several vaccines against respiratory syncytial virus (RSV) have been commercialized recently. Their immediate immunogenicity in various conditions of immunosuppression, including patients receiving allogeneic hematopoietic stem cell transplantation (HSCT), have been reported in 2025 by different teams, including ours. In immunocompromised patients, the duration of vaccinal humoral protection as well as the relevance of seasonal revaccination is still unknown. By analyzing the kinetics of humoral responses after a single dose of bivalent RSVpreF vaccine over 12 months in 71 HSCT recipients, we show that annual revaccination benefits mostly those primarily vaccinated within the early 18 months after HSCT. We also provide a first evaluation of vaccinal clinical effectiveness in HSCT patients.

You can write a PREreview of Relevance of Seasonal Revaccination against Respiratory Syncytial Virus in Hematology Patients: First Insights in Stem Cell Transplant Recipients. A PREreview is a review of a preprint and can vary from a few sentences to a lengthy report, similar to a journal-organized peer-review report.

Before you start

We will ask you to log in with your ORCID iD. If you don’t have an iD, you can create one.